Based on the Office for National Statistics population and the NHS Quality and Outcomes framework 2023-24 around 614,000 adults in England have heart failure. Of these, around 63% (387,000) adults are ...

Dr Sarah Byron discusses how NICE is transforming to ensure more digital health technologies are adopted by the NHS. These ...

Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency TA1064 22 May 2025 22 May ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

People have the right to be involved in discussions and make informed decisions about their care, as described in NICE's information on making decisions about your care. Making decisions using NICE ...

This guidance has been updated and replaced by NICE guideline NG217. Back to top ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

The company has agreed a nationally available price reduction for somapacitan with the Medicines Procurement and Supply Chain. The prices agreed through the framework are commercial in confidence. The ...

NICE is unable to make a recommendation on tislelizumab (Tevimbra) for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy in adults. This is because ...

NICE has today (10 th June) published final draft guidance which recommends several treatment options for around 25,000 people with moderate rheumatoid arthritis that have not responded to ...

The appraisal committee sub-group has prepared final draft guidance (FDG) on linzagolix for treating symptoms of endometriosis and submitted it to NICE. The FDG has been sent to consultees for this ...